Dr. Heidi Overton, President Trump’s nominee to lead the Food and Drug Administration (FDA), appeared before the Senate Health, Education, Labor and Pensions (HELP) Committee on Thursday, Sept. 24, 2026. During the confirmation hearing, Overton addressed questions regarding vaccine safety, the abortion medication mifepristone, and flavored electronic cigarettes, while declining to directly characterize several of President Trump's past statements on health matters as incorrect.
The hearing follows a period of transition for the FDA, which is currently led by an administration that has proposed a 'Make America Healthy Again' agenda. Overton, a physician and White House domestic policy adviser, previously worked at the America First Policy Institute and contributed to a recent executive order that recommended spacing out childhood vaccination schedules. If confirmed, she would succeed Marty Makary, who resigned in May amid reports of falling workplace morale and a 20% reduction in the agency's total staff through buyouts and resignations.
During testimony, Overton stated that "every vaccine on the market right now" is safe and effective, specifically naming the measles, mumps, and rubella (MMR) vaccine. HELP Committee Chairman Bill Cassidy (R-LA) pressed Overton to refute President Trump's past claim that the MMR shot could be "lethal." While Overton defended the vaccine's efficacy and its role in responding to current outbreaks, she did not directly state that the president was wrong. Cassidy, whose vote may be decisive in the committee, noted that Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. had previously backtracked on similar guarantees.
Regarding reproductive health, Democratic and Republican senators questioned Overton on the FDA’s ongoing safety review of mifepristone, a drug used in medication abortions. Sen. Patty Murray (D-WA) cited a 2023 policy paper written by Overton that described telehealth prescriptions of the drug as "dangerous to women." Overton testified that the drug has met FDA safety determinations but stated she would not "prejudge" the current review, which was initiated last year. Sen. Josh Hawley (R-MO) questioned if the FDA was changing its legal position on the drug's safety, to which Overton responded that the safety study is necessary to examine data collected since prescribing rules were eased.
The confirmation of a new FDA commissioner affects approximately 16,000 agency employees and the entire U.S. population, as the agency regulates the nation's food supply, tobacco, vaccines, and pharmaceuticals. For families and medical providers, the leadership at the FDA determines the official guidance for routine childhood immunizations, which Overton noted are currently 97% effective at stopping measles transmission. Changes to these schedules, as proposed by the current administration, could result in parents spending more time and money on additional medical appointments for separated doses.
Patients relying on medication abortion—which is currently the most common method of pregnancy termination in the U.S.—are specifically affected by the agency's ongoing safety review. A decision to reinstate in-person dispensing requirements would impact residents in rural areas, such as the 80% of Alaskan communities cited by Sen. Lisa Murkowski (R-AK), who would face significant barriers to access without telehealth options. Additionally, adult smokers and youth are affected by the FDA's recent approvals of fruit-flavored electronic cigarettes; while Overton defended these approvals as a tool to help adults quit smoking, senators like Susan Collins (R-ME) expressed concern that these products may increase youth vaping rates.
The outcome of this confirmation will set the precedent for how much independence the FDA maintains from White House policy directives. If Overton is confirmed, she will be responsible for balancing the 'Make America Healthy Again' movement’s focus on re-examining food ingredients and vaccines against the administration’s stated goal of reducing regulatory burdens on products like e-cigarettes. The HELP Committee must now decide whether to advance her nomination to the full Senate. Overton requires the support of every Republican on the 21-member panel to advance if all Democrats oppose her, with moderate Republicans Murkowski and Collins yet to announce their positions. Results of the mifepristone safety review are expected to be announced within weeks.